---
layout: default
title: A Multicenter Benchmark of Multiple Instance Learning Models for Lymphoma Subtyping from HE-stained Whole Slide Images
---

# A Multicenter Benchmark of Multiple Instance Learning Models for Lymphoma Subtyping from HE-stained Whole Slide Images

**arXiv**: [2512.14640v1](https://arxiv.org/abs/2512.14640) | [PDF](https://arxiv.org/pdf/2512.14640.pdf)

**ä½œè€…**: Rao Muhammad Umer, Daniel Sens, Jonathan Noll, Christian Matek, Lukas Wolfseher, Rainer Spang, Ralf Huss, Johannes Raffler, Sarah Reinke, Wolfram Klapper, Katja Steiger, Kristina Schwamborn, Carsten Marr

**åˆ†ç±»**: cs.CV, cs.AI

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

**å¤‡æ³¨**: 17 pages

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºé¦–ä¸ªå¤šä¸­å¿ƒæ·‹å·´ç˜¤åˆ†åž‹åŸºå‡†æ•°æ®é›†ï¼Œç³»ç»Ÿè¯„ä¼°ç—…ç†åŸºç¡€æ¨¡åž‹ä¸Žå¤šå®žä¾‹å­¦ä¹ èšåˆå™¨åœ¨HEæŸ“è‰²å…¨åˆ‡ç‰‡å›¾åƒä¸Šçš„æ€§èƒ½ã€‚**

**å…³é”®è¯**: `æ·‹å·´ç˜¤åˆ†åž‹` `å…¨åˆ‡ç‰‡å›¾åƒåˆ†æž` `å¤šå®žä¾‹å­¦ä¹ ` `ç—…ç†åŸºç¡€æ¨¡åž‹` `å¤šä¸­å¿ƒåŸºå‡†` `HEæŸ“è‰²å›¾åƒ` `æ³¨æ„åŠ›æœºåˆ¶` `Transformerèšåˆ`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. çŽ°æœ‰æ·‹å·´ç˜¤è¯Šæ–­ä¾èµ–å¤šæ¨¡æ€æ£€æµ‹ï¼Œæˆæœ¬é«˜ã€è€—æ—¶é•¿ï¼Œä¸”ç¼ºä¹å¤šä¸­å¿ƒHEå›¾åƒåˆ†åž‹åŸºå‡†ã€‚
2. è®ºæ–‡æå‡ºé¦–ä¸ªå¤šä¸­å¿ƒæ·‹å·´ç˜¤åŸºå‡†æ•°æ®é›†ï¼Œå¹¶ç³»ç»Ÿè¯„ä¼°ç—…ç†åŸºç¡€æ¨¡åž‹ä¸Žå¤šå®žä¾‹å­¦ä¹ èšåˆå™¨çš„ç»„åˆã€‚
3. æ¨¡åž‹åœ¨åˆ†å¸ƒå†…æµ‹è¯•é›†ä¸Šå‡†ç¡®çŽ‡è¶…80%ï¼Œä½†åˆ†å¸ƒå¤–æ€§èƒ½é™è‡³çº¦60%ï¼Œæ­ç¤ºæ³›åŒ–æŒ‘æˆ˜ã€‚

## ðŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

åŠæ—¶å‡†ç¡®çš„æ·‹å·´ç˜¤è¯Šæ–­å¯¹æŒ‡å¯¼ç™Œç—‡æ²»ç–—è‡³å…³é‡è¦ã€‚æ ‡å‡†è¯Šæ–­å®žè·µç»“åˆè‹æœ¨ç²¾-ä¼Šçº¢ï¼ˆHEï¼‰æŸ“è‰²å…¨åˆ‡ç‰‡å›¾åƒä¸Žå…ç–«ç»„åŒ–ã€æµå¼ç»†èƒžæœ¯å’Œåˆ†å­é—ä¼ å­¦æ£€æµ‹æ¥ç¡®å®šæ·‹å·´ç˜¤äºšåž‹ï¼Œè¿™ä¸€è¿‡ç¨‹éœ€è¦æ˜‚è´µè®¾å¤‡ã€ç†Ÿç»ƒäººå‘˜å¹¶å¯¼è‡´æ²»ç–—å»¶è¿Ÿã€‚æ·±åº¦å­¦ä¹ æ–¹æ³•å¯é€šè¿‡ä»Žå¸¸è§„å¯ç”¨çš„HEæŸ“è‰²åˆ‡ç‰‡ä¸­æå–è¯Šæ–­ä¿¡æ¯æ¥ååŠ©ç—…ç†å­¦å®¶ï¼Œä½†å¤šä¸­å¿ƒæ•°æ®ä¸Šçš„æ·‹å·´ç˜¤åˆ†åž‹ç»¼åˆåŸºå‡†ä»ç¼ºä¹ã€‚åœ¨è¿™é¡¹å·¥ä½œä¸­ï¼Œæˆ‘ä»¬æå‡ºäº†é¦–ä¸ªå¤šä¸­å¿ƒæ·‹å·´ç˜¤åŸºå‡†æ•°æ®é›†ï¼Œæ¶µç›–å››ç§å¸¸è§æ·‹å·´ç˜¤äºšåž‹å’Œå¥åº·å¯¹ç…§ç»„ç»‡ã€‚æˆ‘ä»¬ç³»ç»Ÿè¯„ä¼°äº†äº”ç§å…¬å¼€å¯ç”¨çš„ç—…ç†åŸºç¡€æ¨¡åž‹ï¼ˆH-optimus-1ã€H0-miniã€Virchow2ã€UNI2ã€Titanï¼‰ä¸ŽåŸºäºŽæ³¨æ„åŠ›ï¼ˆAB-MILï¼‰å’ŒåŸºäºŽTransformerï¼ˆTransMILï¼‰çš„å¤šå®žä¾‹å­¦ä¹ èšåˆå™¨åœ¨ä¸‰ç§æ”¾å¤§å€æ•°ï¼ˆ10xã€20xã€40xï¼‰ä¸‹çš„ç»„åˆã€‚åœ¨åˆ†å¸ƒå†…æµ‹è¯•é›†ä¸Šï¼Œæ¨¡åž‹åœ¨æ‰€æœ‰æ”¾å¤§å€æ•°ä¸‹å®žçŽ°äº†è¶…è¿‡80%çš„å¤šç±»å¹³è¡¡å‡†ç¡®çŽ‡ï¼Œæ‰€æœ‰åŸºç¡€æ¨¡åž‹è¡¨çŽ°ç›¸ä¼¼ï¼Œä¸¤ç§èšåˆæ–¹æ³•ç»“æžœç›¸å½“ã€‚æ”¾å¤§å€æ•°ç ”ç©¶è¡¨æ˜Žï¼Œ40xåˆ†è¾¨çŽ‡å·²è¶³å¤Ÿï¼Œæ›´é«˜åˆ†è¾¨çŽ‡æˆ–è·¨æ”¾å¤§å€æ•°èšåˆæœªå¸¦æ¥æ€§èƒ½æå‡ã€‚ç„¶è€Œï¼Œåœ¨åˆ†å¸ƒå¤–æµ‹è¯•é›†ä¸Šï¼Œæ€§èƒ½æ˜¾è‘—ä¸‹é™è‡³çº¦60%ï¼Œçªæ˜¾äº†æ˜¾è‘—çš„æ³›åŒ–æŒ‘æˆ˜ã€‚ä¸ºæŽ¨è¿›è¯¥é¢†åŸŸï¼Œéœ€è¦è¦†ç›–æ›´å¤šç½•è§æ·‹å·´ç˜¤äºšåž‹çš„æ›´å¤§è§„æ¨¡å¤šä¸­å¿ƒç ”ç©¶ã€‚æˆ‘ä»¬æä¾›äº†ä¸€ä¸ªè‡ªåŠ¨åŒ–åŸºå‡†æµ‹è¯•æµç¨‹ä»¥ä¿ƒè¿›æ­¤ç±»æœªæ¥ç ”ç©¶ã€‚

## ðŸ”¬ æ–¹æ³•è¯¦è§£

è®ºæ–‡é‡‡ç”¨å¤šå®žä¾‹å­¦ä¹ æ¡†æž¶å¤„ç†å…¨åˆ‡ç‰‡å›¾åƒï¼Œå°†æ¯ä¸ªåˆ‡ç‰‡è§†ä¸ºå®žä¾‹åŒ…ï¼Œæ¯ä¸ªå®žä¾‹å¯¹åº”å›¾åƒå—ã€‚æ ¸å¿ƒæ–¹æ³•ç»“åˆé¢„è®­ç»ƒçš„ç—…ç†åŸºç¡€æ¨¡åž‹ï¼ˆå¦‚H-optimus-1ã€Virchow2ç­‰ï¼‰æå–ç‰¹å¾ï¼Œç„¶åŽä½¿ç”¨åŸºäºŽæ³¨æ„åŠ›çš„AB-MILæˆ–åŸºäºŽTransformerçš„TransMILèšåˆå™¨æ•´åˆå®žä¾‹çº§ç‰¹å¾ï¼Œç”Ÿæˆåˆ‡ç‰‡çº§é¢„æµ‹ã€‚å…³é”®åˆ›æ–°åœ¨äºŽé¦–æ¬¡åœ¨å¤šä¸­å¿ƒæ·‹å·´ç˜¤æ•°æ®é›†ä¸Šç³»ç»Ÿæ¯”è¾ƒå¤šç§åŸºç¡€æ¨¡åž‹ä¸Žèšåˆå™¨ï¼Œå¹¶ç ”ç©¶æ”¾å¤§å€æ•°çš„å½±å“ã€‚ä¸ŽçŽ°æœ‰æ–¹æ³•ç›¸æ¯”ï¼Œè¯¥æ–¹æ³•é¿å…äº†ä»Žå¤´è®­ç»ƒï¼Œåˆ©ç”¨å…¬å¼€åŸºç¡€æ¨¡åž‹ï¼Œå¹¶é€šè¿‡åŸºå‡†æµ‹è¯•æä¾›äº†æ ‡å‡†åŒ–è¯„ä¼°ã€‚

## ðŸ“Š å®žéªŒäº®ç‚¹

åœ¨åˆ†å¸ƒå†…æµ‹è¯•é›†ä¸Šï¼Œæ‰€æœ‰æ¨¡åž‹ç»„åˆåœ¨10xã€20xã€40xæ”¾å¤§å€æ•°ä¸‹å‡å®žçŽ°è¶…è¿‡80%çš„å¤šç±»å¹³è¡¡å‡†ç¡®çŽ‡ï¼Œè¡¨æ˜Ž40xåˆ†è¾¨çŽ‡å·²è¶³å¤Ÿä¸”æ— éœ€æ›´é«˜åˆ†è¾¨çŽ‡ã€‚ç„¶è€Œï¼Œåˆ†å¸ƒå¤–æµ‹è¯•é›†æ€§èƒ½å¤§å¹…ä¸‹é™è‡³çº¦60%ï¼Œçªæ˜¾æ¨¡åž‹æ³›åŒ–èƒ½åŠ›ä¸è¶³ï¼Œæ˜¯æœªæ¥ç ”ç©¶çš„å…³é”®æŒ‘æˆ˜ã€‚

## ðŸŽ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶å¯åº”ç”¨äºŽç—…ç†å­¦è¾…åŠ©è¯Šæ–­ï¼Œå¸®åŠ©ä»Žå¸¸è§„HEæŸ“è‰²åˆ‡ç‰‡ä¸­å¿«é€Ÿè¯†åˆ«æ·‹å·´ç˜¤äºšåž‹ï¼Œå‡å°‘å¯¹æ˜‚è´µè¾…åŠ©æ£€æµ‹çš„ä¾èµ–ï¼ŒåŠ é€Ÿè¯Šæ–­æµç¨‹ï¼Œå°¤å…¶åœ¨èµ„æºæœ‰é™æˆ–è¿œç¨‹åŒ»ç–—åœºæ™¯ä¸­å…·æœ‰å®žé™…ä»·å€¼ã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> Timely and accurate lymphoma diagnosis is essential for guiding cancer treatment. Standard diagnostic practice combines hematoxylin and eosin (HE)-stained whole slide images with immunohistochemistry, flow cytometry, and molecular genetic tests to determine lymphoma subtypes, a process requiring costly equipment, skilled personnel, and causing treatment delays. Deep learning methods could assist pathologists by extracting diagnostic information from routinely available HE-stained slides, yet comprehensive benchmarks for lymphoma subtyping on multicenter data are lacking. In this work, we present the first multicenter lymphoma benchmarking dataset covering four common lymphoma subtypes and healthy control tissue. We systematically evaluate five publicly available pathology foundation models (H-optimus-1, H0-mini, Virchow2, UNI2, Titan) combined with attention-based (AB-MIL) and transformer-based (TransMIL) multiple instance learning aggregators across three magnifications (10x, 20x, 40x). On in-distribution test sets, models achieve multiclass balanced accuracies exceeding 80% across all magnifications, with all foundation models performing similarly and both aggregation methods showing comparable results. The magnification study reveals that 40x resolution is sufficient, with no performance gains from higher resolutions or cross-magnification aggregation. However, on out-of-distribution test sets, performance drops substantially to around 60%, highlighting significant generalization challenges. To advance the field, larger multicenter studies covering additional rare lymphoma subtypes are needed. We provide an automated benchmarking pipeline to facilitate such future research.

